7,549.94

+173.08

+2.35%

52,389.75

+1,104.02

+2.15%

25,253.14

+673.74

+2.74%

2,840.81

+86.71

+3.15%

4.8640

+0.0050

+0.10%

19.92

-5.72

-22.31%

4,148.80

+34.30

+0.83%

75,224.47

+75.49

+0.10%

Crude Oil Dec 26

86.46

-0.39

-0.45%

US Private Equity

10,772.76

+11.86

+0.11%

NasdaqCM - Delayed Quote USD

Exicure, Inc. (XCUR)

0.8903 -0.0595 (-6.26%)

At close: November 9 at 4:00:00 PM EST

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

GlobeNewswire 1mo ago

XCUR
-9.31%
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

GlobeNewswire 3mo ago

XCUR
-9.31%
Exicure Announces Board and Committee Changes

GlobeNewswire 4mo ago

XCUR
-9.31%
^IXIC
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

GlobeNewswire 4mo ago

XCUR
-9.31%
^IXIC
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

GlobeNewswire 5mo ago

XCUR
-9.31%
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

GlobeNewswire 6mo ago

XCUR
-9.31%
179530.KQ
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

GlobeNewswire 7mo ago

XCUR
-9.31%
Exicure, Inc. Reports Full Year 2025 Financial Results

GlobeNewswire 7mo ago

XCUR
-9.31%
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

GlobeNewswire 8mo ago

XCUR
-9.31%
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

GlobeNewswire 9mo ago

XCUR
-9.31%
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

GlobeNewswire 10mo ago

XCUR
-9.31%

Mobilize your Website

View Site in Mobile | Classic

Share by: